Global Biosimilars Week: Message of Mr Sudarshan Jain (October 2021)Read More
Smart use of off-patent medicines will be critical to rebuild healthcare systems successfully post-Covid (October 2021)
07 October, Athens, Greece. Health systems have been severely jolted by COVID-19, causing widespread disruption to the provision of health care worldwide. As countries shift to investment in healthcare system recovery and ongoing management of COVID-19, off-patent medicines will be… Read More
Annual Conference Opening Remarks Suzette Kox (October 2021)
It is my great pleasure and honor to welcome you all to the Joint Annual Conference of Medicines for Europe and IGBA here in Athens under the title Goal 2030: Access For All...Read More
Global regulators and coalition of pharma and vaccine manufacturing associations come together to discuss COVID-19 pandemic response (July 2021)
On 7 July 2021, the International Coalition of Medicines Regulatory Authorities (ICMRA) is hosting a (virtual) workshop titled ‘Enabling Manufacturing Capacity in the COVID-19 Pandemic’ with representatives from the leading association bodies representing biotech firms, developing and industrialized countries vaccine… Read More
IGBA Launches a Whitepaper: a Vision for the Global Generic and Biosimilar Medicines Industry (July 2021)
Today the International Generic and Biosimilar Medicines Association (IGBA) is launching a whitepaper: A Vision for the Global Generic and Biosimilar Medicines Industry, which covers the strong contribution of this pharmaceutical sector to global health outcomes and economies, the opportunities,… Read More
IGBA Applauds UK MHRA Biosimilar Guidance Revision: Science-driven Evolution for Sustainable Access to Biologics (May 2021)
The International Generic and Biosimilar medicines Association (IGBA), which represents global manufacturers of generic and biosimilar medicines, welcomes the UK MHRA publication of its updated guidance on the licensing of biosimilar products (10 May 2021). This publication marks a positive… Read More
Our vision is to promote the widest possible access to generic and biosimilar medicines with high quality, safety and efficacy, support international harmonized pathways for the registration of those medicines, and a strong commitment by members to standards agreed by the International Council for Harmonization (ICH) and WHO accredited regulators.
In an era when increasing demands are being made on the world’s healthcare services, generic and biosimilar medicines provide a major benefit to society by ensuring patient access to quality, safe and effective medicines while reducing the cost of pharmaceutical care.
The International Generic Pharmaceutical Alliance (IGPA) was founded in March 1997 as an international network of generic medicines associations. To reflect the evolving nature of the industry, in September 2015, IGPA incorporated under Swiss Law, and at the same time changed the name of the organization to the International Generic and Biosimilar Medicines Association (IGBA).